AT108 / Asgard Therapeutics - LARVOL DELTA

AT-108, an adenoviral vector based therapy for in situ cancer to dendritic cell reprogramming, leads to durable antitumor activity as a single agent and in combination with immune checkpoint blockade [WITHDRAWN] (ESMO 2025) - No abstract available

Checkpoint block • Checkpoint inhibition • Combination therapy • Viral vector • Oncology

Asgard Therapeutics' study published in Science showing proof-of-concept and strong anti-tumor responses via in vivo cell reprogramming with lead program AT-108 (PRNewswire) - "Novel data shows that AT-108 reprograms tumor cells, directly within the immunosuppressed tumor microenvironment, into an immunogenic cell fate, which mounts strong anti-tumor, antigen-specific responses and durable tumor shrinkage even upon metastatic rechallenge....The study entitled, In vivo dendritic cell reprogramming for cancer immunotherapy, also shows the systematic selection of an optimal delivery system for expression of key reprogramming factors in the tumor, which led to the nomination of Asgard's lead program."

Preclinical • Oncology • Solid Tumor